Basic Information
STALICLA is a clinical-stage precision molecular neuroscience company advancing two precision autism assets, STP1 and STP2, through its DEPI Precision Neuro platform. Following the in-licensing of mavoglurant from Novartis in 2023, STALICLA has also established an advanced mGLuR5 NAM platform, offering multifaceted late-stage clinical development opportunities.
STALICLA SA
Geneva,CantonofGeneva,Switzerland
15~50 people
January 01, 2017
--